.png){kind=icon}
.png){kind=icon}
Return
Low Attenuation Plaque-Mediated NSTEMI in a Patient with Sarcoidosis and High Lp(a)
.png){kind=icon}
PRE
AI
R
E
M
DOI：10.1016/j.jacl.2026.06.014.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Risk scores and CAC scoring can miss patients with "non-calcific” plaque • Our patient had CAC of zero and borderline PREVENT risk despite extensive plaque • CCTA with AI-QP detects lipid-rich vulnerable plaque beyond calcium scoring • Highest published LAP (30%) in a patient with sarcoidosis, high Lp(a), and NSTEMI • High Lp(a) plus one risk enhancer may warrant CCTA even when CAC is zero
Journal
IF:
4.6
Papers:
2.5K
Citations:
4.3K
Organization
Cited Papers